Literature DB >> 20112379

A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis.

G Farina1, D Lafyatis, R Lemaire, R Lafyatis.   

Abstract

OBJECTIVE: Improved outcome measures in systemic sclerosis (SSc) are critical to finding active therapeutics for this disease. The modified Rodnan skin thickness score (MRSS) is the current standard for evaluating skin disease in SSc, but it is not commonly used in the clinical setting, in part because it requires specialized training to perform accurately and consistently. The purpose of this study was to investigate whether skin gene expression might serve as a more objective surrogate outcome measure to supplement skin score evaluations.
METHODS: Skin RNAs from a group of patients with diffuse cutaneous SSc were studied for expression levels of genes known to be regulated by transforming growth factor beta (TGFbeta) and interferon (IFN). These levels were correlated with the MRSS, using multiple regression analyses to obtain best-fit models.
RESULTS: Skin expression of the TGFbeta-regulated genes cartilage oligomeric matrix protein (COMP) and thrombospondin 1 (TSP-1) correlated moderately well with the MRSS, but the addition of other TGFbeta-regulated genes failed to significantly improve best-fit models. IFN-regulated genes were also found to correlate with the MRSS, and the addition of interferon-inducible 44 (IFI44) and sialoadhesin (Siglec-1) to COMP and TSP-1 in multiple regression analyses significantly improved best-fit models, achieving an R(2) value of 0.89. These results were validated using an independent group of skin biopsy samples. Longitudinal scores using this 4-gene biomarker indicated that it detects change over time that corresponds to changes in the MRSS.
CONCLUSION: We describe a 4-gene predictor of the MRSS and validate its performance. This objective measure of skin disease could provide a strong surrogate outcome measure for patient care and for clinical trials.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20112379      PMCID: PMC3018285          DOI: 10.1002/art.27220

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  33 in total

1.  Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement.

Authors:  A Scheja; M Wildt; F A Wollheim; A Akesson; T Saxne
Journal:  Rheumatology (Oxford)       Date:  2000-10       Impact factor: 7.580

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis.

Authors:  S Sato; M Hasegawa; K Takehara
Journal:  J Dermatol Sci       Date:  2001-10       Impact factor: 4.563

4.  IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent.

Authors:  Mallika Kaviratne; Matthias Hesse; Mary Leusink; Allen W Cheever; Stephen J Davies; James H McKerrow; Lalage M Wakefield; John J Letterio; Thomas A Wynn
Journal:  J Immunol       Date:  2004-09-15       Impact factor: 5.422

5.  Transforming growth factor beta/Smad3 signaling regulates IRF-7 function and transcriptional activation of the beta interferon promoter.

Authors:  Jing Qing; Cheng Liu; Lisa Choy; Rui-Yun Wu; Joseph S Pagano; Rik Derynck
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

6.  Global expression analysis of the fibroblast transcriptional response to TGFbeta.

Authors:  H Gardner; D Strehlow; L Bradley; R Widom; A Farina; A de Fougerolles; J Peyman; V Koteliansky; J H Korn
Journal:  Clin Exp Rheumatol       Date:  2004 Jan-Feb       Impact factor: 4.473

7.  Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta.

Authors:  G Farina; R Lemaire; P Pancari; J Bayle; R L Widom; R Lafyatis
Journal:  Ann Rheum Dis       Date:  2008-04-13       Impact factor: 19.103

8.  TGF-beta and CTGF have overlapping and distinct fibrogenic effects on human renal cells.

Authors:  Elizabeth Gore-Hyer; Daniel Shegogue; Malgorzata Markiewicz; Shianlen Lo; Debra Hazen-Martin; Eddie L Greene; Gary Grotendorst; Maria Trojanowska
Journal:  Am J Physiol Renal Physiol       Date:  2002-10

9.  Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK.

Authors:  Shi-wen Xu; Sarah L Howat; Elisabetta A Renzoni; Alan Holmes; Jeremy D Pearson; Michael R Dashwood; George Bou-Gharios; Christopher P Denton; Roland M du Bois; Carol M Black; Andrew Leask; David J Abraham
Journal:  J Biol Chem       Date:  2004-03-23       Impact factor: 5.157

10.  Gamma interferon is the lymphokine and beta interferon the monokine responsible for inhibition of fibroblast collagen production and late but not early fibroblast proliferation.

Authors:  M R Duncan; B Berman
Journal:  J Exp Med       Date:  1985-08-01       Impact factor: 14.307

View more
  75 in total

1.  Proteomic analysis identification of a pattern of shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis.

Authors:  Francesco Del Galdo; M Alexander Shaw; Sergio A Jimenez
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

2.  Local skin gene expression reflects both local and systemic skin disease in patients with systemic sclerosis.

Authors:  Lisa M Rice; Giuseppina Stifano; Jessica Ziemek; Robert Lafyatis
Journal:  Rheumatology (Oxford)       Date:  2015-09-05       Impact factor: 7.580

3.  [Fresolimumab: A new treatment option for systemic scleroderma on the horizon?].

Authors:  B Homey
Journal:  Hautarzt       Date:  2015-10       Impact factor: 0.751

Review 4.  Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence?

Authors:  Giuseppina Stifano; Romy Beatriz Christmann
Journal:  Curr Rheumatol Rep       Date:  2016-01       Impact factor: 4.592

Review 5.  Biomarkers in the management of scleroderma: an update.

Authors:  Giuseppina Abignano; Maya Buch; Paul Emery; Francesco Del Galdo
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

Review 6.  Personalized medicine in systemic sclerosis: facts and promises.

Authors:  Rucsandra Dobrota; Carina Mihai; Oliver Distler
Journal:  Curr Rheumatol Rep       Date:  2014-06       Impact factor: 4.592

7.  Lenabasum for Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis.

Authors:  Monique Hinchcliff
Journal:  Arthritis Rheumatol       Date:  2020-07-04       Impact factor: 10.995

Review 8.  Mechanistic biomarkers for clinical decision making in rheumatic diseases.

Authors:  William H Robinson; Tamsin M Lindstrom; Regina K Cheung; Jeremy Sokolove
Journal:  Nat Rev Rheumatol       Date:  2013-02-19       Impact factor: 20.543

Review 9.  Targeted therapies for systemic sclerosis.

Authors:  Christopher P Denton; Voon H Ong
Journal:  Nat Rev Rheumatol       Date:  2013-04-09       Impact factor: 20.543

Review 10.  Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.

Authors:  Colin Ligon; Laura K Hummers
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.